A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs E 2027 (Primary)
- Indications Dementia; Lewy body disease
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 02 Dec 2019 Planned End Date changed from 31 Mar 2020 to 23 Nov 2023.
- 02 Dec 2019 Planned primary completion date changed from 11 Mar 2020 to 8 May 2020.
- 18 Jul 2018 According to an Eisai Inc media release, results will be presented at Alzheimer's Association International Conference (AAIC) 2018.